Akebia Therapeutics (NASDAQ:AKBA) Lowered to “Sell” Rating by StockNews.com
StockNews.com cut shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) from a hold rating to a sell rating in a report released on Friday. A number of other equities research analysts have also issued reports on AKBA. HC Wainwright reaffirmed a “buy” rating and issued a $7.50 price target on shares of Akebia Therapeutics in […]
StockNews.com cut shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) from a hold rating to a sell rating in a report released on Friday. A number of other equities research analysts have also issued reports on AKBA. HC Wainwright reaffirmed a “buy” rating and issued a $7.50 price target on shares of Akebia Therapeutics in […]
